Evidence-Based Cancer Resources: Articles, Dictionaries, and Access Tools
This is not a medical tourism blog. We publish source-cited clinical content, plain-language medical dictionaries, and access-intelligence tools for patients, families, and referring physicians navigating international oncology.
Every article either answers a specific clinical or practical question or fills a documented gap in English-language oncology access content. Browse by audience — patients, physicians, or researchers — or jump directly to our Chinese medical document question pages.
What Makes This Different
Common assumption: "All cancer information sites say the same thing."
Reality: Most coordination sites don't publish honest data that could reduce their own patient volume. We do. That is the difference. Every article here either fills a documented gap in English-language oncology access content or provides a source-cited reference tool you can use without a hospital recommendation.
This page is NOT for patients seeking a single promotional recommendation, or for readers looking for a general cancer overview. It IS for patients, families, referring physicians, and researchers who want source-cited, honest information about international oncology access — without medical tourism claims.
- Which article explains real-world CAR-T outcomes without exaggeration?
- What do 符合, 考虑为, 倾向, and 不除外 mean in a Chinese pathology report?
- How do I match a Chinese drug name to its international generic name?
- Which translation mistakes are most dangerous in Chinese medical reports?
- How do I compare the total cost of treatment across countries?
- How can I tell if an article is source-cited and not promotional?
Start Here: Our Most Useful Reference Tools
Three resources that define what we do — source-cited dictionaries, honest assessments, and living documents updated regularly.
What Do 符合, 考虑为, 倾向, and 不除外 Mean in a Chinese Pathology Report?
These four terms describe different levels of diagnostic certainty — from "consistent with" to "cannot exclude." A question-based reference with pinyin, English equivalents, and plain-language explanations.
How Do I Match a Chinese Cancer Drug Name to Its International Generic Name?
Confused by a Chinese prescription or treatment plan? This reference helps you identify a Chinese cancer drug by brand name, active ingredient, or generic name — with confirmation sources for each match.
Why Your Oncologist Might Not Refer You to China: A Decision Framework
Competitors won't write this article because it might cost them patients. We wrote it because it earns trust. Why Western oncologists rarely refer to China — and when a referral conversation is worth having.
All Articles & Reference Tools
Source-cited resources organized by audience and topic. Each one fills a documented gap in English-language oncology access content.
Chinese Medical Document Questions — Answered
Each page answers one specific question about a Chinese medical document. All pages are live and available in English; Persian and Arabic versions are also live on the site.
What Do 符合, 考虑为, 倾向, and 不除外 Mean in a Chinese Pathology Report?
These four terms describe different levels of diagnostic certainty — from "consistent with" to "cannot exclude." Mistaking one for another can change how you understand your diagnosis.
How Do I Match a Chinese Cancer Drug Name to Its International Generic Name?
Chinese prescriptions often use brand names or transliterations. This reference helps you identify the active ingredient and find the international generic name — with a confirmation source for each match.
Which Chinese Medical Terms Are Most Dangerous to Mistranslate?
Ten high-risk terms where a mistranslation can change the meaning of a report — probability language, diagnostic certainty, imaging findings, tumor grade, and lab results.
What Do the Terms in a Chinese Hospital Discharge Summary Mean?
Diagnosis, procedures, medications, discharge status, and follow-up recommendations — the document you hand to your home oncologist.
How Do I Read a Chinese Oncology Laboratory Report?
Blood counts, tumor markers, and molecular results — each term covered from test name and units to plain-language meaning.
What Do the Terms in a Chinese CAR-T Treatment Record Mean?
Product names, cell types, preparation, infusion, complications, and follow-up terms.
What Do the Terms in Chinese Clinical Trial Documents Mean?
Registration, recruitment, inclusion/exclusion criteria, informed consent, and study status.
How Do I Read a Chinese CT, MRI, or PET-CT Report?
Imaging terms in Chinese with international equivalents and plain-language translations.
How Do I Read Dosage and Units in a Chinese Oncology Prescription?
Dosage, units, frequency, route, and duration terms in Chinese oncology prescriptions.
How Are Mutations and Biomarkers Described in Chinese Molecular Reports?
Mutation, variant, biomarker, and actionability terms in Chinese molecular reports.
For Patients & Families
Practical, honest guides for patients navigating international treatment decisions.
Why Your Oncologist Might Not Refer You to China
Seven scenarios where the decision to travel should pause — and what to verify before committing. A decision framework, not a destination guide.
Referring Your Patient to China: A Clinical Protocol
An evidence-led look at why Western oncologists rarely refer patients to China, what has genuinely changed, and when a referral conversation may be worth having.
CAR-T Clinical Trial Registry in China
A framework for verifying trial status, recruitment, and international access — not a fabricated registry. Explains what a registered trial does and does not mean.
CAR-T Remission Rates: How to Read the Numbers Before You Travel
Published real-world ranges and what ECOG, prior lines, and disease burden mean for your expected outcome. Source-cited, no exaggerated claims.
Treatment Cost Planning: Total Cost of Care
Understand total cost of care vs. quoted treatment price. What is included, what is excluded, and how to request an itemized quotation.
What Happens After CAR-T: The 12-Month Follow-Up Protocol
Month-by-month follow-up protocol with a downloadable checklist for your local oncologist after returning home.
Medical Visa Requirements for Cancer Treatment
Country-by-country requirements, required documents, processing times, and invitation letter templates — updated quarterly.
TIL Therapy After PD-1 Failure
Where international patients can access TIL therapy — China, Singapore, and trial pathways explained.
For Referring Physicians
Clinical protocols, regulatory comparisons, and emergency guidance for oncologists who refer internationally.
CAR-T Manufacturing in China vs USA: A Technical Comparison
Vector design, transduction protocols, and QC standards — for physicians comparing manufacturing quality across regions.
Referring Your Patient to China: A Clinical Protocol
From initial evaluation to exit report — with a downloadable referral template and continuity-of-care guidance.
CRS Management Away from Home: A Guide for Local Physicians
When a patient returns home after CAR-T and develops CRS — tocilizumab protocols, steroid dosing, and ICU transfer criteria.
NGS Results Interpretation for Therapy Matching
How to find the best therapy match from NGS results — PD-L1, MSI-H, TMB, BRCA, HER2. Decision tree with reference card.
The Physician's Dilemma: Ethics of Referring Patients Abroad
When is it ethical to refer abroad? An academic analysis for oncologists, peer-reviewed by medical ethicists.
For Researchers & Clinical Analysts
Data-first articles, trial registries, and response rate databases for the research community.
Response Rate Database: Real-World CAR-T Outcomes by Cancer Type
Reference table with PubMed sources. ORR, CR, PFS, OS by cancer type, by CAR construct, by line of therapy.
Solid Tumor CAR-T: Why It Failed Before and What's Different in 2026
Tumor microenvironment, armored CAR-T, and combination protocols — technical deep-dive.
BCLC 2025 Update: Liver Cancer Staging and Treatment Strategy
Updated Barcelona Clinic Liver Cancer staging system for 2025 with revised treatment algorithms.
Super-Deep Tumor Profiling
Sequencing 100,000+ genomic regions per tumor — beyond standard NGS panels.
PROTACs & Molecular Degraders
A completely new way to eliminate cancer-causing proteins permanently.
Physician Reference Shelf
Curated clinical resources for referring oncologists. Source-cited summaries, downloadable checklists, trial-matching data, and emergency protocols.
Referring Your Patient to China: A Clinical Protocol
From initial evaluation to exit report. Downloadable referral template. Continuity of care across borders.
CRS Management Away from Home
When a patient returns home after CAR-T and develops CRS — downloadable emergency protocol card.
NGS Results Interpretation for Therapy Matching
PD-L1, MSI-H, TMB, BRCA, HER2 — decision tree with downloadable reference card.
Why Your Oncologist Might Not Refer You to China
A decision framework for when travel should pause — useful for both patients and referring physicians.
Access Intelligence: Match Need → Article Type
Instead of browsing everything, find the right resource for your specific need.
| Your Need | Required Capability | Recommended Resource | Status |
|---|---|---|---|
| Understand a Chinese pathology report | Reference of diagnostic certainty terms with English equivalents | What Do 符合, 考虑为, 倾向, and 不除外 Mean? | Available |
| Identify a Chinese drug name | Brand/generic/active-ingredient lookup with sources | Match a Chinese Drug Name to Its Generic Name | Available |
| Avoid dangerous translation errors | Reference of high-risk terms with examples | Which Chinese Medical Terms Are Dangerous to Mistranslate? | Available |
| Decide whether to travel to China | Decision framework and verification checklist | Why Your Oncologist Might Not Refer You | Available |
| Understand CAR-T outcomes without exaggeration | Source-cited real-world outcome ranges | CAR-T Remission Rates | Available |
| Verify trial status and international access | Registry framework and verification workflow | CAR-T Clinical Trial Registry | Available |
| Refer a patient internationally (physician) | Protocols, templates, regulatory comparisons | Referring Your Patient to China | Available |
Frequently Asked Questions
Common questions about the Evidence Hub and our editorial process.
Are these articles source-cited?
Yes. Every article cites its sources inline, with links to the original registry, journal, or authoritative source. The E-E-A-T Box at the top of each article shows the publication date and last review date. We do not claim medical review by a physician network unless a documented review has occurred.
What makes these articles different from other sites?
Most oncology information sites publish content optimized for search volume, not for filling real clinical gaps. We do the opposite. Each article either fills a documented gap in English-language oncology access content or provides a source-cited reference tool. Articles like "Why Your Oncologist Might Not Refer You to China" and the Chinese Medical Document Question Pages are examples of content competitors won't write because it could reduce their patient volume — or because they don't have the language expertise.
Which articles are for physicians vs patients?
Every article is tagged with its primary audience. Patient-facing articles are written in plain language with practical guidance (costs, visas, follow-up, dictionaries). Physician-facing articles include clinical protocols, technical comparisons, and regulatory frameworks. You can browse by audience using the filter navigation above.
Are the Chinese Medical Document Question Pages available in other languages?
Currently, Persian (FA) and Arabic (AR) versions are live on the site. The English versions are also live. Turkish (TR) and Russian (RU) versions are planned and will follow the same structure: original Chinese term, pinyin, standard English equivalent, and plain-language explanation.
How often are articles updated?
Reference tools (dictionaries, trial registries, cost data) are reviewed and updated as new terms or data become available. Articles are updated when the underlying sources change. The last-reviewed date is shown at the top of each article.
Can I suggest a term or topic for the dictionaries?
Yes. If you have received a Chinese medical document and encountered a term that is not yet covered, you can submit a suggestion through our contact page. We prioritize suggestions that come with a specific document context or a documented source.
Sources & Editorial Standards
- CancerCareE Editorial Policy — Source-cited content; no claim of medical review unless documented.
- ClinicalTrials.gov — Primary source for trial registries and NCT numbers.
- PubMed / NCBI — Peer-reviewed literature referenced across all articles.
- NCCN, ESMO, ASCO, ELN, IMWG — Clinical guideline sources.
- FDA and NMPA public registries — Regulatory approval data.
- Chinese-language medical dictionaries and hospital documentation standards — Source for term definitions.
Read Enough? Let's Look at Your Specific Case.
Every article here is general information. Your case is specific. Request a free information review and our team will help you understand what to verify, what to ask, and how to compare options.
Related Reading
Continue exploring CancerCareE's source-cited resources.
What Do 符合, 考虑为, 倾向, and 不除外 Mean?
Decode Chinese pathology certainty terms with English equivalents.
Read the Reference →How Do I Match a Chinese Drug Name to Its Generic Name?
Match Chinese drug names to international generic names.
Read the Reference →Why Your Oncologist Might Not Refer You
A decision framework for when travel should pause.
Read Framework →CancerCareE FAQ
How the platform works.
Read FAQ →